Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 2/20 | 0.51 |
| ▸ | MLNR | O43193 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.46 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10034611 | 0.91 | SPPL2A (0.54) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL12050564 | 0.91 | SPPL2A (0.51) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL469816 | 0.91 | SPPL2A (0.51) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL2906368 | 0.89 | SPPL2A (0.56) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL28799797 | 0.89 | SPPL2A (0.56) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL2906364 | 0.89 | SPPL2A (0.56) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL13567460 | 0.87 | SPPL2A (0.55) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL20998328 | 0.87 | SPPL2A (0.53) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL13964089 | 0.86 | SPPL2A (0.53) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL1813919 | 0.86 | SPPL2A (0.53) | SPPL2AMLNRABCB11LMNACTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643976-B2 | Solvates of darunavir | AUROBINDO PHARMA LTD. (IN) | 2017-05-09 | — | — | US | disclosed |
| US-9643976-B2 | Solvates of darunavir | AUROBINDO PHARMA LTD. (IN) | 2017-05-09 | — | — | US | disclosed |
| US-9127029-B2 | Process for preparation of substantially pure fosamprenavir calcium and its intermediates | LUPIN LIMITED (IN) | 2015-09-08 | — | — | US | disclosed |
| US-9127029-B2 | Process for preparation of substantially pure fosamprenavir calcium and its intermediates | LUPIN LIMITED (IN) | 2015-09-08 | — | — | US | disclosed |
| US-20150141382-A1 | NOVEL SOLVATES OF DARUNAVIR | AUROBINDO PHARMA LIMITED (IN) | 2015-05-21 | — | — | US | disclosed |
| US-20150141382-A1 | NOVEL SOLVATES OF DARUNAVIR | AUROBINDO PHARMA LIMITED (IN) | 2015-05-21 | — | — | US | disclosed |
| US-8877947-B2 | Process for preparation of substantially pure fosamprenavir calcium and its intermediates | LUPIN LIMITED (IN) | 2014-11-04 | — | — | US | disclosed |
| US-8877947-B2 | Process for preparation of substantially pure fosamprenavir calcium and its intermediates | LUPIN LIMITED (IN) | 2014-11-04 | — | — | US | disclosed |
| US-20140256959-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES | LUPIN LIMITED (IN) | 2014-09-11 | — | — | US | disclosed |
| US-20140256959-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES | LUPIN LIMITED (IN) | 2014-09-11 | — | — | US | disclosed |
| US-20130174651-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES | LUPIN LIMITED (IN) | 2013-07-11 | — | — | US | disclosed |
| US-20130174651-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES | LUPIN LIMITED (IN) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141382-A1 | NOVEL SOLVATES OF DARUNAVIR | DARS1, SAMHD1, SARS1 | SPPL2A 4249/4885MLNR 4299/4885ABCB11 101/4885 |
| US-20140256959-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES | PLCB3, ITPR3, ITPR2 | SPPL2A 1150/4885MLNR 2161/4885ABCB11 3996/4885 |
| US-20130174651-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES | PLCB3, ITPR3, ITPR2 | SPPL2A 1150/4885MLNR 2161/4885ABCB11 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.